Sofia Genta, University of Toronto

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial.
Targeted oncology · 2024
Antibody–drug conjugates: in search of partners of choice
Trends in cancer · 2023
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

All 7 publications

Latest funding

Monitoring the response to Lung Cancer Immunotherapy using an mDETECT Liquid Biopsy
CIHR · 2026 · Co-investigator
$1,128,374

All 1 grants and awards

7 publications.

01

Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial.

Salawu A, Malone ER, Al-Ezzi E, Genta S, Vornicova O, Wang L, Arones L, Phillips M, Lee J, Watson GA, Gupta AA, Abdul Razak AR

Targeted oncology20241 citations

DOI: 10.1007/s11523-024-01076-7 PMID: 38890222

02

Antibody–drug conjugates: in search of partners of choice

Jesús Fuentes‐Antrás, Sofia Genta, Abi Vijenthira, Lillian L. Siu

Trends in cancer2023208 citationsOpen Access

DOI: 10.1016/j.trecan.2023.01.003 PMID: 36746689

03

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.

Vieito M, Moreno V, Spreafico A, Brana I, Wang JS, Preis M, Hernández T, Genta S, Hansen AR, Doger B, Galvao V, Lenox L, Brown RJ, Kalota A, Mehta J, Pastore F, Patel B, Mistry P, Gu J, Lauring J, Patel MR

Clinical cancer research : an official journal of the American Association for Cancer Research202385 citations

DOI: 10.1158/1078-0432.ccr-23-0092 PMID: 37491846

04

Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials.

Sanz-Garcia E, Genta S, Chen X, Ou Q, Araujo DV, Abdul Razak AR, Hansen AR, Spreafico A, Bao H, Wu X, Siu LL, Bedard PL

JCO precision oncology202310 citations

DOI: 10.1200/po.22.00509 PMID: 37027812

05

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).

Genta S, Lajkosz K, Yee NR, Spiliopoulou P, Heirali A, Hansen AR, Siu LL, Saibil S, Stayner LA, Yanekina M, Sauder MB, Keshavarzi S, Salawu A, Vornicova O, Butler MO, Bedard PL, Razak ARA, Rottapel R, Chruscinski A, Coburn B, Spreafico A

Journal of experimental & clinical cancer research : CR202310 citationsFirst authorOpen Access

DOI: 10.1186/s13046-023-02851-6 PMID: 37865776

06

Patient-derived cancer models: Valuable platforms for anticancer drug testing.

Genta S, Coburn B, Cescon DW, Spreafico A

Frontiers in oncology202236 citationsFirst authorOpen Access

DOI: 10.3389/fonc.2022.976065 PMID: 36033445

07

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.

Muniz TP, Araujo DV, Savage KJ, Cheng T, Saha M, Song X, Gill S, Monzon JG, Grenier D, Genta S, Allen MJ, Arteaga DP, Saibil SD, Butler MO, Spreafico A, Hogg D

Cancers202115 citationsOpen Access

DOI: 10.3390/cancers14010089 PMID: 35008256

Monitoring the response to Lung Cancer Immunotherapy using an mDETECT Liquid Biopsy

Co-investigatorCIHR2026Project Grant

Principal investigators: Mueller, Christopher R

Keywords: Chemotherapy; Immunotherapy; Liquid Biopsy; Lung Cancer; Response Directed Therapy; Selection

$1,128,374

From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.

Frequent collaborators

Robert Rottapel and Rob Rottapel: 346 shared papers
Lillian Siu and Philippe Bedard: 302 shared papers
Anna Spreafico and Lillian Siu: 280 shared papers
Anna Spreafico and Philippe Bedard: 180 shared papers
Lillian Siu and Lisa Wang: 100 shared papers
Samuel Saibil and Sam Saibil: 99 shared papers
David Cescon and Philippe Bedard: 97 shared papers
Enrique Sanz Garcia and Philippe Bedard: 67 shared papers
Bryan Coburn and Anna Spreafico: 56 shared papers
David Cescon and Lillian Siu: 56 shared papers
Anna Spreafico and Enrique Sanz Garcia: 53 shared papers
Philippe Bedard and Lisa Wang: 53 shared papers
Bryan Coburn and Lillian Siu: 51 shared papers
Lillian Siu and Enrique Sanz Garcia: 51 shared papers
Abha Gupta and Philippe Bedard: 45 shared papers
Bryan Coburn and Philippe Bedard: 37 shared papers
Anna Spreafico and Sareh Keshavarzi: 36 shared papers
Anna Spreafico and Abha Gupta: 35 shared papers
Abha Gupta and Lillian Siu: 35 shared papers
Lillian Siu and Sareh Keshavarzi: 30 shared papers
Anna Spreafico and Lisa Wang: 27 shared papers
Anna Spreafico and Sam Saibil: 27 shared papers
Anna Spreafico and Samuel Saibil: 26 shared papers
Anna Spreafico and David Cescon: 16 shared papers
Robert Rottapel and Lisa Wang: 15 shared papers
Lisa Wang and Rob Rottapel: 15 shared papers
Lillian Siu and Sam Saibil: 8 shared papers
Lillian Siu and Samuel Saibil: 7 shared papers
Lillian Siu and Abdulazeez Salawu: 6 shared papers
Anna Spreafico and Sofia Genta: 5 shared papers
Sareh Keshavarzi and Sam Saibil: 5 shared papers
Anna Spreafico and Abdulazeez Salawu: 4 shared papers
Philippe Bedard and Abdulazeez Salawu: 4 shared papers
Lillian Siu and Sofia Genta: 3 shared papers
Bryan Coburn and Sofia Genta: 2 shared papers
Anna Spreafico and Sabrina Gill: 2 shared papers
Abha Gupta and Esmail Al-Ezzi: 2 shared papers
Philippe Bedard and Sofia Genta: 2 shared papers
Lisa Wang and Esmail Al-Ezzi: 2 shared papers
Esmail Al-Ezzi and Abdulazeez Salawu: 2 shared papers
Sofia Genta and Abdulazeez Salawu: 2 shared papers
Sofia Genta and Sam Saibil: 2 shared papers
Robert Rottapel and Bryan Coburn: 1 shared paper
Robert Rottapel and Sofia Genta: 1 shared paper
Bryan Coburn and Rob Rottapel: 1 shared paper
David Cescon and Sofia Genta: 1 shared paper
Abha Gupta and Sofia Genta: 1 shared paper
Lillian Siu and Abi Vijenthira: 1 shared paper
Samuel Saibil and Sabrina Gill: 1 shared paper
Samuel Saibil and Sofia Genta: 1 shared paper
Enrique Sanz Garcia and Sofia Genta: 1 shared paper
Sareh Keshavarzi and Sofia Genta: 1 shared paper
Lisa Wang and Sofia Genta: 1 shared paper
Sabrina Gill and Sofia Genta: 1 shared paper
Esmail Al-Ezzi and Sofia Genta: 1 shared paper
Abi Vijenthira and Sofia Genta: 1 shared paper
Sofia Genta and Rob Rottapel: 1 shared paper

Department of Medicine
Biostatistics Division
Department of Laboratory Medicine & Pathobiology
Institute of Medical Science
Department of Radiation Oncology
Department of Medical Biophysics
MacIsaac School of Nursing
Other

1 shared papers, latest 2024

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mention

Subject: Prospective PhD student Dear Professor Genta, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial." (2024), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Sofia Genta

Research

Latest papers

Latest funding

Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial.

Antibody–drug conjugates: in search of partners of choice

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.

Tumor-Na&#xef;ve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials.

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).

Patient-derived cancer models: Valuable platforms for anticancer drug testing.

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.

Monitoring the response to Lung Cancer Immunotherapy using an mDETECT Liquid Biopsy

Frequent collaborators

Anna Spreafico

Lillian Siu

Abdulazeez Salawu

Sam Saibil

Bryan Coburn

Philippe Bedard

Rob Rottapel

Samuel Saibil

Enrique Sanz Garcia

Sareh Keshavarzi

Lisa Wang

Sabrina Gill

Esmail Al-Ezzi

Robert Rottapel

Abi Vijenthira

Andrzej Chruscinski

David Cescon

Abha Gupta

Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials.